News Releases

September 26, 2023
YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
September 15, 2023
YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection
September 5, 2023
YS Biopharma to Participate in Citi's 18th Annual Biopharma Conference
August 24, 2023
YS Biopharma Announces Purchase of Shares by Company Officers
August 15, 2023
YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024
August 10, 2023
YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023
July 26, 2023
YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023
July 21, 2023
YS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023
June 1, 2023
YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA
May 18, 2023
YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023
Print Page
Email Alerts
RSS Feeds
Contact IR
Site Map Terms of Use Privacy

Contact Info

YS Biopharma Co., Ltd.

11 Firstfield Road Suite A
Gaithersburg, Maryland 20878 USA

Tel: +1 (301) 208 8823
Fax: +1 (301) 208 8827

bjinfo@yishengbio.com